Insider trade

Officer sold ~$299K of AMGN shares in the open market

Traded Nov 12, 2025 · Filed Nov 14, 2025

AmgenAMGN

~$299K
Reported value · 890 sh @ $336.2422: 7,082
Holds after · shares reported: +21.1%
stock since the trade · S&P 500 +11.8%, $336.28 → $407.27 on Oct 1

Why it stands out

Amgen's SVP, Business Development sold $299K of Amgen shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 12, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 14, 2025

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$299,256

Shares × reported transaction price

Timing vs results

8 days after results of Nov 4, 2025, 83 days before results of Feb 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $336.28 on Nov 12, 2025, within 1% of its 52-week high, after a 13% rise over the previous 30 trading days

52-week range $258.59 (Jan 6, 2025) to $338.45 (Nov 11, 2025), 97% of the way up, from 250 adjusted closes. 30 trading days earlier: $298.50 on Oct 1, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references dividend reinvestment

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Imdelltra on Nov 19, 2025, 7 days after this trade.

New use approved (efficacy supplement). Active ingredient: Tarlatamab-Dlle. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.2%	-1.9%	+2.2%
30 days	-3.4%	+1.3%	-4.7%
90 days	+8.8%	+1.4%	+7.4%
180 days	-0.1%	+10.5%	-10.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0000318154-25-000082
Filed / recorded: Nov 14, 2025, 12:29 AM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: AMGEN INC
Issuer CIK: 318154
Ticker: AMGN
Reporting person: Rachna Khosla
Relationship: Officer
Officer title: SVP, Business Development
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 12, 2025
Transaction code: S
Shares / units: 890
Price per share: $336.2422
Acquired / disposed: Disposed (D)
Shares owned after: 7,082
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported is an average price. The prices ranged from $336.2219 to $336.30 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.